Alkermes plc has entered into a definitive agreement to sell its development and manufacturing facility and related assets in Athlone, Ireland to Novo Nordisk for $92.5 million, subject to customary closing conditions.   Alkermes and Novo Nordisk also plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing of the transaction, which may continue through the end of 2025. Alkermes will continue to retain a...